BioPharmSignal logoBioPharmSignal

Biotech News

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

UroGen Pharma (URGN)UroGen PharmaEarnings

Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,

Related news

URGNUroGen Pharma2026-08-05 12:00 EST

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

URGNUroGen Pharma2026-07-29 12:00 EST

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

EXELExelixis2026-07-22 20:30 EST

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

KURAKura Oncology2026-08-05 11:30 EST

Kura Oncology to Report Second Quarter Financial Results

IMCRImmunocore Holdings plc2026-07-30 11:00 EST

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

RVMDRevolution Medicines2026-07-29 20:05 EST

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

View all latest news

UroGen Pharma

Uro-Oncology Franchise UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease. Commercial ZUSDURI...

Recent company news

URGNUroGen Pharma2026-08-20 11:00 EST

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

URGNUroGen Pharma2026-08-17 12:00 EST

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

URGNUroGen Pharma2026-08-05 12:00 EST

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

URGNUroGen Pharma2026-07-29 12:00 EST

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

URGNUroGen Pharma2026-07-15 12:00 EST

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

Stock data

Close
46.86 USD
Market cap
1.29B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States